Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumps
| Autor: | SJ Tyler, Shelley J Allen, Robertson Alan George Simpson, Gordon K. Wilcock, David Dawbarn |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
Guinea Pigs Biophysics Spodoptera Biochemistry PC12 Cells law.invention Cell Line Mice In vivo law Internal medicine Nerve Growth Factor medicine Infusion pump Animals Humans Cholinergic neuron Infusion Pumps Clinical Trials as Topic business.industry In vitro Recombinant Proteins Rats Endocrinology Nerve growth factor nervous system Recombinant DNA Cholinergic Biological Assay Rabbits business Baculoviridae Function (biology) Protein Binding |
| Zdroj: | Journal of biochemical and biophysical methods. 47(3) |
| ISSN: | 0165-022X |
| Popis: | Nerve growth factor (NGF) has been suggested to be of therapeutic benefit to patients with Alzheimer’s disease. One of the early changes in this disease is a loss of cholinergic function within the brain, and NGF is able to rescue cholinergic neurons both in vitro and in vivo. We describe the production of recombinant human β-NGF (rhNGF), using baculovirus infection of insect cells; its purification, formulation and subsequent stability for use in clinical trials. Tests were also carried out to monitor release of protein from infusion pumps and catheters for intracerebroventricular administration (icv). Initial problems with non-specific binding were overcome using a blocking formula. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect